Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has been assigned an average broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. Sonoma Pharmaceuticals’ rating score has declined by 100% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a one year consensus price target of $8.00 for the company and are predicting that the company will post ($0.65) earnings per share for the current quarter, according to Zacks. Zacks has also given Sonoma Pharmaceuticals an industry rank of 206 out of 265 based on the ratings given to related companies.
A number of equities research analysts have recently issued reports on SNOA shares. Zacks Investment Research raised Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, January 10th. Maxim Group set a $11.00 target price on Sonoma Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 17th. Finally, Benchmark started coverage on Sonoma Pharmaceuticals in a research report on Thursday, December 28th. They set a “speculative buy” rating and a $10.00 target price on the stock.
A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Deutsche Bank AG bought a new stake in Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,141 shares of the company’s stock, valued at approximately $137,000. Deutsche Bank AG owned approximately 0.54% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 13.24% of the company’s stock.
Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) opened at $3.87 on Friday. The company has a market capitalization of $23.88, a price-to-earnings ratio of -1.34 and a beta of 1.24. The company has a quick ratio of 3.83, a current ratio of 4.62 and a debt-to-equity ratio of 0.01. Sonoma Pharmaceuticals has a 12 month low of $3.50 and a 12 month high of $8.25.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Wednesday, February 7th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.10). The company had revenue of $4.84 million for the quarter, compared to analyst estimates of $4.50 million. Sonoma Pharmaceuticals had a negative return on equity of 70.95% and a negative net margin of 70.46%. research analysts forecast that Sonoma Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.
WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/sonoma-pharmaceuticals-inc-snoa-given-8-00-average-target-price-by-analysts.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.